282 results
8-K
EX-10.2
PALI
Palisade Bio Inc
3 May 24
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
4:56pm
or accounting duties), the expense of any annual audit and the fees and expenses incurred in connection with the listing of the Registrable
8-K
EX-10.1
PALI
Palisade Bio Inc
3 May 24
Palisade Bio Announces $4 Million Private Placement Priced At-The- Market Under Nasdaq Rules
4:56pm
, year-end audit adjustments, except where such violations could not, individually or in the aggregate, reasonably be expected to have a Material Adverse
424B3
PALI
Palisade Bio Inc
5 Apr 24
Prospectus supplement
5:12pm
Market that our audit committee does not have three (3) independent members as a result of recent director resignations. If we fail to timely appoint … an independent director that meets the Nasdaq Stock Market Requirements for audit committees, Nasdaq could delist our common stock.
Our success
8-K
PALI
Palisade Bio Inc
27 Mar 24
Results of Operations and Financial Condition
4:45pm
the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company was not in compliance with the audit committee … requirements set forth in Nasdaq Listing Rule 5605.
More specifically, as of the date of the Notice, the audit committee consists of only two (2
8-K
EX-3.1
yyzi86
6 Mar 24
Departure of Directors or Certain Officers
4:35pm
8-K
EX-10.01
3jqt1 orbp9q85ra3uwk
11 Sep 23
Entry into a Material Definitive Agreement
3:30pm
8-K
EX-10.01
vy4bd a3zjc
8 Sep 23
Entry into a Material Definitive Agreement
4:54pm
8-K
u7b4pja 3hqr3
9 Jun 23
Entry into a Material Definitive Agreement
9:38am